Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have earned a consensus rating of “Buy” from the nine ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $51.75.
Several brokerages recently issued reports on VERA. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price target on shares of Vera Therapeutics in a research report on Monday, September 16th.
Read Our Latest Report on Vera Therapeutics
Insider Buying and Selling at Vera Therapeutics
Hedge Funds Weigh In On Vera Therapeutics
Large investors have recently made changes to their positions in the company. Public Employees Retirement Association of Colorado purchased a new position in shares of Vera Therapeutics during the 2nd quarter worth about $135,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vera Therapeutics in the 2nd quarter valued at about $163,000. Ameritas Investment Partners Inc. raised its holdings in shares of Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares in the last quarter. Cetera Advisors LLC bought a new stake in shares of Vera Therapeutics in the 1st quarter valued at about $235,000. Finally, Quarry LP bought a new stake in shares of Vera Therapeutics in the 2nd quarter valued at about $235,000. 99.21% of the stock is owned by hedge funds and other institutional investors.
Vera Therapeutics Trading Up 1.9 %
Shares of NASDAQ VERA opened at $42.78 on Wednesday. The firm’s 50 day moving average price is $37.35 and its 200-day moving average price is $39.11. The company has a market cap of $2.34 billion, a PE ratio of -20.87 and a beta of 0.99. Vera Therapeutics has a 52-week low of $9.24 and a 52-week high of $50.78. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, equities research analysts expect that Vera Therapeutics will post -2.57 EPS for the current fiscal year.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
See Also
- Five stocks we like better than Vera Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Are Penny Stocks a Good Fit for Your Portfolio?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.